Free Newsletter
Ex-FDA chief Henney could return
Put another name on your possible-FDA-chief list: Dr. Jane Henney (photo), a professor at the University of Cincinnati who ran the agency for the last couple years of President Bill Clinton's administration. The Cincinnati Enquirer quotes unnamed sources saying that Obama's transition team contacted Henney about the potential job, and she expressed interest in serving. Henney herself refused to comment.
If Henney were selected, she would become yet another Clintonite tapped for duty in the Obama administration, joining CIA pick Leon Panetta, who was Clinton's chief of staff; attorney general candidate Eric Holder, who was Clinton's deputy AG; chief of staff Rahm Emmanuel, a top Clinton adviser; economic council pick Larry Summers, Clinton's Treasury Secretary; and others.
After she worked at the FDA, Henney served as VP and provost at the University of Cincinnati Academic Health Center, a job she relinquished last year because of budget strains and a "changing clinical environment" for cutting-edge research, which made the institution's goals markedly different from those she signed onto, she said.
Henney's claim to fame at the FDA--among Republicans at least--is the fact that she ran the agency while the abortion pill RU-486 was approved. Industry groups and lawmakers both praised her work there, however, the Enquirer reports. She helped speed the pace of drug approvals and cut down on red tape, they said.
- read the story for more
Related Articles:
FDA chief to step down
Sharfstein looks to be on FDA short list
Survey says: Nissen or Rost for Commish
Sweep the FDA clean, Stupak says
Obama considers CNN's Gupta for Surgeon General
Comments
Excellent candidate. Her learning curve would be rather brief compared to bringing in someone new who has never served in FDA/NIH or run a large complex organization.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





